

## KAZIA THERAPEUTICS LIMITED

### Appendix 4E Preliminary final report

#### 1. COMPANY DETAILS

Name of entity:	Kazia Therapeutics Limited
ABN:	37 063 259 754
Reporting period:	For the year ended 30 June 2019
Previous period:	For the year ended 30 June 2018

#### 2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

				\$
Revenues from ordinary activities	down	100.0%	to	-
Loss from ordinary activities after tax attributable to the owners of Kazia Therapeutics Limited	up	70.1%	to	(10,270,264)
Loss for the year attributable to the owners of Kazia Therapeutics Limited	up	70.1%	to	(10,270,264)

##### Dividends

There were no dividends paid, recommended or declared during the current financial period.

##### Comments

The loss for the consolidated entity after providing for income tax amounted to \$10,270,264 (30 June 2018: \$6,039,242).

#### 3. NET TANGIBLE ASSETS

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.13	9.63

#### 4. CONTROL GAINED OVER ENTITIES

Not applicable.

#### 5. LOSS OF CONTROL OVER ENTITIES

Not applicable.

#### 6. DIVIDENDS

##### Current period

There were no dividends paid, recommended or declared during the current financial period.

##### Previous period

There were no dividends paid, recommended or declared during the previous financial period.

#### 7. DIVIDEND REINVESTMENT PLANS

Not applicable.

#### 8. DETAILS OF ASSOCIATES AND JOINT VENTURE ENTITIES

Not applicable.

#### 9. FOREIGN ENTITIES

Details of origin of accounting standards used in compiling the report:

Not applicable.

## 10. AUDIT QUALIFICATION OR REVIEW

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

## 11. ATTACHMENTS

Details of attachments (if any):

The Directors' report and financial statements of Kazia Therapeutics Limited for the year ended 30 June 2019 is attached.

## 12. SIGNED



---

Mr Lain Ross

Chairman

Date: 29 August 2019